Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Leukocyte Disease Clear all
Recruiting Phase 2 Interventional

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

NCT07588568
View directory record Official record
Conditions
EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
Interventions
Upadacitinib 30mg Dose, Upadacitinib Matching Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 11, 2026, 9:44 PM EDT
Completed Phase 1 Interventional

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

NCT00002759
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclosporine, irinotecan hydrochloride, phenobarbital
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 11, 2026, 9:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Image the Esophagus Using the OFDI Capsule

NCT02204150
View directory record Official record
Conditions
Barrett's Esophagus, Eosinophilic Esophagitis
Interventions
OFDI Capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 11, 2026, 9:44 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

NCT06598462
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo
Biological · Other
Lead sponsor
Uniquity One (UNI)
Industry
Eligibility
18 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
38
States / cities
Dothan, Alabama • Glendale, Arizona • Peoria, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 11, 2026, 9:44 PM EDT
Recruiting No phase listed Observational

Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)

NCT03980886
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
1 Year to 65 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 11, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Results available

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

NCT01390402
View directory record Official record
Conditions
Leukemia, Chronic Myelogenous Leukemia
Interventions
Fludarabine, Busulfan, NK cell infusion:, Interleukin-2, Anti-Thymocyte Globulin, Allogeneic related Stem Cell Transplant, Tacrolimus, Methotrexate, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 11, 2026, 9:44 PM EDT
Not listed No phase listed Observational

International Registry for Severe Chronic Neutropenia

NCT00004342
View directory record Official record
Conditions
Neutropenia
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
3 Months and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
5
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 11, 2026, 9:44 PM EDT
Withdrawn Phase 1 Interventional

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

NCT00886496
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
recombinant human mannose-binding lectin
Biological
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Orange, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 11, 2026, 9:44 PM EDT
Completed Not applicable Interventional

Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

NCT00002049
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Annandale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 9:44 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Esophageal Absorption in EoE

NCT02314455
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
D-xylose
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 11, 2026, 9:44 PM EDT
Recruiting Phase 3 Interventional

Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia

NCT02484248
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
Ketotifen, Placebo
Drug
Lead sponsor
Craig A. Friesen, MD
Other
Eligibility
8 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 11, 2026, 9:44 PM EDT
Terminated Not applicable Interventional Results available

A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children

NCT01458418
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Montelukast, placebo, 5 mg Montelukast
Drug · Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 11, 2026, 9:44 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

NCT02384395
View directory record Official record
Conditions
HIV, Acute HIV Infection
Interventions
Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 11, 2026, 9:44 PM EDT
Terminated Phase 2 Interventional

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

NCT00230334
View directory record Official record
Conditions
Eosinophilia, Hypereosinophilic Syndrome
Interventions
Gleevec
Drug
Lead sponsor
Steven E. Coutre
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 11, 2026, 9:44 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

NCT00005802
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, filgrastim, therapeutic allogeneic lymphocytes, cytarabine, etoposide, fludarabine phosphate, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 11, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Results available

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

NCT03496571
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 11, 2026, 9:44 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

NCT01290887
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
48
States / cities
Scottsdale, Arizona • Anaheim, California • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 11, 2026, 9:44 PM EDT
Completed No phase listed Observational

Effect of Body Mass on Filgrastim Pharmacokinetics

NCT01719432
View directory record Official record
Conditions
Hematological Malignancy, Neutropenia
Interventions
Not listed
Lead sponsor
Aaron Cumpston, PharmD, BCOP
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 11, 2026, 9:44 PM EDT
Terminated Early Phase 1 Interventional

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

NCT05284032
View directory record Official record
Conditions
Platelet Refractoriness, Hematologic Malignancy
Interventions
isatuximab 10 mg/kg
Drug
Lead sponsor
Firas El Chaer, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 11, 2026, 9:44 PM EDT
Terminated Not applicable Interventional Results available

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

NCT02145039
View directory record Official record
Conditions
Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia
Interventions
Fludarabine, Cyclophosphamide, Total Body Irradiation, Haploidentical stem cell transplant
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 74 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 11, 2026, 9:44 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Surface EMG Testing on Swallowing in EoE Patients

NCT07156357
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Surface Electromyography, Fiberoptic Endoscopic Evaluation of Swallowing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 11, 2026, 9:44 PM EDT
Completed Phase 2 Interventional Results available

Milk Patch for Eosinophilic Esophagitis

NCT02579876
View directory record Official record
Conditions
Eosinophilic Esophagitis, Milk Allergy
Interventions
Viaskin Milk 500 mcg, Viaskin Placebo
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 11, 2026, 9:44 PM EDT
Terminated Phase 1 Interventional

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

NCT05769959
View directory record Official record
Conditions
Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
Interventions
RO7515629, tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 11, 2026, 9:44 PM EDT
Active, not recruiting No phase listed Observational

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

NCT04174742
View directory record Official record
Conditions
Breast, Breast Cancer
Interventions
pegfilgrastim
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2041
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 11, 2026, 9:44 PM EDT